With the inhibition of KDM6B, GSK-J4 induces H3K27 methylation and shows potent antitumor efficacy in several cancers including glioma and leukemia [118,119], where GSK-J4 might be involved in the downregulation of cyclic-AMP response element–binding protein [120]. Here, KDM6B is linked to cancer.